Healthcare
Cartesian Therapeutics, Inc.(RNAC)
Live Price
Offline$6.26
-2.34% today
1Y Change
-2.56%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $160.00M
- Revenue Growth
- -92.8%
- EPS Growth
- -67.9%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cartesian Therapeutics, Inc. (RNAC) is a Healthcare stock with a market cap of $160.00M and listed on NASDAQ. The stock last traded around $6.26 and down 2.6% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -92.8%, EPS growth of -67.9%, a dividend yield of 0.0%. What stands out right now is revenue -92.8%, EPS -67.9%, free cash flow -142.3% with operating margin -5144.5% and ROIC -31.1%. Valuation already assumes a fairly strong business story at price/sales 92.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RNAC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-92.8% vs +7.6% peer median
Operating Margin
Below sector median
-5144.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -92.8% and EPS is at -67.9%, with operating margin around -5144.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -14.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -10.8% | -19.2% | +15.0% |
2026 Mar 9, 2026 | -68.3% | -5.2% | -18.7% | -30.4% |
2025 Nov 6, 2025 | -70.4% | +4.2% | -4.2% | -8.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNAC
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RNAC Max Drawdown
-57.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RNAC and SPY.
Company Overview
Cartesian Therapeutics, Inc.
NASDAQ Global Market
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
- Leadership
- Carsten Brunn
- IPO Date
- Jun 22, 2016
- Employees
- 66
- Street Address
- 65 Grove Street
- Mailing
- Watertown, MA, 02472
- Region
- Watertown, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 923 1400
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 92.9
- Price/Book
- โ
Growth
- Revenue
- -92.8%
- EPS
- -67.9%
- Free Cash Flow
- -142.3%
Profitability
- Gross Margin
- -621.0%
- Operating Margin
- -5144.5%
- Net Margin
- -8550.6%
- ROE
- 194.1%
- ROIC
- -31.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 7.65
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.